Clinical Trials

QPS extends US phase I clinical trial capabilities

Contract research organization (CRO) QPS has expanded its US-based phase I clinical trial capabilities to support the increasing requirements of its pharmaceutical, biotechnology and CRO partners.

BMS’ Opdivo plus Yervoy fails to improve OS in lung cancer study

Bristol-Myers Squibb (BMS) announced that its cancer drug combination Opdivo plus Yervoy has failed to improve overall survival (OS) rate in the phase 3 CheckMate -451 study.

Poxel begins part 2 of phase 1a study for NASH treatment PXL065

Biopharmaceutical company Poxel has stared part 2 of the phase 1a study for PXL065, a deuterium-stabilized R-stereoisomer of pioglitazone.

Actinogen Medical enrolls last patient in phase 2 Alzheimer’s trial

Actinogen Medical has enrolled the final patient into XanADu, a phase 2 clinical trial to evaluate Xanamem in the treatment of patients with mild Alzheimer’s disease.

Pfizer and Merck’s avelumab fails to improve OS or PFS in Javelin ovarian cancer trial

Pfizer and Merck have announced that avelumab alone or in combination with pegylated liposomal doxorubicin (PLD) has failed to improve overall survival (OS) or progression-free survival (PFS) rate in phase III Javelin Ovarian 200 trial.

GlycoMimetics enrolls first patient in Phase III clinical trial of uproleselan

GlycoMimetics has dosed the first patient in its Phase 3 clinical trial of uproleselan (GMI-1271) in relapsed/refractory acute myeloid leukemia (AML).

AstraZeneca’s Imfinzi fails to improve OS in Mystic lung cancer trial

AstraZeneca’s Imfinzi (durvalumab) monotherapy and the combination of Imfinzi with remelimumab have failed to improve overall survival (OS) rate in phase III Mystic lung cancer trial.

Seattle Genetics begins blood cancer trial with SEA-BCMA

Seattle Genetics has dosed the d first patient in a phase 1 clinical trial evaluating the safety and tolerability of SEA-BCMA for patients with relapsed or refractory multiple myeloma (MM).

Merck’s Keytruda improves overall survival in phase 3 esophageal cancer trial

Merck has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) significantly improved overall survival (OS) rate in the phase 3 Keynote-181 esophageal cancer trial.